A pragmatiC sTrategy to Promote actIVity and Enhance Quality of Life AFTER Transcatheter Aortic Valve Replacement



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:9/21/2018
Start Date:November 7, 2017
End Date:February 2020
Contact:Stephanie A Smith, MA
Email:Stephanie.anne.smith@vumc.org
Phone:615-936-0815

Use our guide to learn which trials are right for you!

A pragmatiC sTrategy to Promote actIVity and Enhance Quality of Life AFTER Transcatheter Aortic Valve Replacement (ACTIVE AFTER TAVR): A Pilot Study

This study is being performed in patients who have undergone transcatheter aortic valve
replacement (TAVR) for aortic stenosis. The goal is to obtain pilot and feasibility data on a
novel post-procedure rehabilitation strategy, including a daily activity goal using a fitness
tracking device (Fitbit Alta HR) and in-home resistance training exercises targeting muscles
related to activities of daily living. We will evaluate the effect of these interventions on
physical performance and several quality of life domains.

The study will be conducted in three phases. Subjects who have been treated commercially with
TAVR with a SAPIEN 3 valve and are being discharged to home will be eligible for Phase 1.
Once consented prior to discharge, patients will complete the KCCQ, PROMIS Questionnaires, 5m
walk, chair stand, and handgrip tests. During phase 1, all subjects will have a Fitbit and
answer quality of life questions on the iPad about their activities and quality of life.
After 30 days, the subject will return to complete the PROMIS Questionnaires, 5m walk, chair
stand, balance tests, and handgrip tests, as well as a KCCQ. If the subject has consistently
provided data throughout Phase 1, they will be asked to continue on to Phases 2 and 3 and
complete a 6 minute walk test at this baseline visit. For Phase 2, subjects will be
randomized to one of two arms. In one arm, they will have a daily activity goal and
resistance exercises; in the other arm, there will not be a daily activity goal and no
resistance exercises given. After 6 weeks, the subject will return to complete the 5m walk, 6
minute walk test, chair stand, balance tests, and handgrip tests, PROMIS Questionnaires, as
well as a KCCQ. Five months after enrollment into Phase 2, subjects will be given a Fitbit to
track their daily activity for 1 week (Phase 3). They will also complete a KCCQ, PROMIS
Questionnaires, and end of study questionnaire.

Inclusion Criteria:

Phase 1 - Starts after the TAVR procedure and prior to discharge • Patients treated
commercially with TAVR with a SAPIEN 3 valve

Phases 2 and 3 - Starts at 30 day post-TAVR follow-up visit

• Patients enrolled in Phase 1

Exclusion Criteria:

Phase 1 - Starts after the TAVR procedure and prior to discharge

- Stroke during or immediately after the TAVR procedure prior to discharge

- Inability to walk

- Non-English speaking (because the mobile app and CAT questionnaires are only in
English)

- Physical or neuropsychiatric limitations that would prevent proficient use of the
study tools and successful completion of the physical and quality of life assessments.
These limitations may include, but are not limited to: blindness, neuropathy, severe
tremor or disabling motor deficit, cognitive impairment (documentation of dementia in
the medical record), or illiteracy.

- Unwillingness or inability of the subject to provide informed consent for Phase 1 (no
LARs allowed)

- Planned discharge from hospital to skilled nursing or rehabilitation facility

Phases 2 and 3 - Starts at 30 day post-TAVR follow-up visit

- All exclusion criteria from Phase 1 apply

- Stroke during Phase 1

- Residing in a skilled nursing facility at the 30 day post-TAVR follow-up visit

- Patients with unreliable use of the iPad mobile app or Fitbit during Phase 1 (e.g. not
wearing the Fitbit at least 10 waking hours a day for at least 5 days a week)

- Unwillingness or inability of the subject to provide informed consent for Phases 2/3
(no LARs allowed)
We found this trial at
5
sites
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Sammy Elmariah, MD
Phone: 617-643-1374
?
mi
from
Boston, MA
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Brian R Lindman, MD
Phone: 615-936-1720
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Fred Welt, MD
Phone: 801-585-2975
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Megan Coylewright, MD
Phone: 603-650-8239
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Morristown, New Jersey 07960
Principal Investigator: Linda Gillam, MD
?
mi
from
Morristown, NJ
Click here to add this to my saved trials